Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02132247 · ClinicalTrials.gov registry record · Phase 4

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

A Phase 4 study of Athletic Injuries, sponsored by IBSA Institut Biochimique.

Completed
Registry status
Phase 4
Development phase
104
Enrollment target
10
Study locations

NCT02132247: Completed Phase 4 study of Athletic Injuries, sponsored by IBSA Institut Biochimique.

NCT02132247 is a Phase 4 study of Athletic Injuries that has completed, run by IBSA Institut Biochimique. The registered enrollment target is 104 participants, below the 188-participant average among 3 other Athletic Injuries trials with a reported enrollment target (45% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02132247, a Phase 4 study of Athletic Injuries, has completed, sponsored by IBSA Institut Biochimique.

COMPLETED
Registry status
Phase 4
Development phase
104 participants
Enrollment target
10
Study locations

Study Summary

The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.

Primary Outcome

None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.

Conditions Studied

Interventions

  • DRUG Diclofenac hydroxyethylpyrrolidine

Study Locations (10)

Utah

  • Utah Valley Pediatrics - Orem
  • J. Lewis Research Inc./Foothill Family Clininc - Salt Lake City
  • J. Lewis Research Inc./FirstMed East - Salt Lake City
  • J. Lewis Research Inc./Foothill Family Clinic South - Salt Lake City
  • Legacy Point Family Medicine - West Point

Arkansas

  • Applied Research Center of Arkansas - Little Rock

Florida

  • SCORE Physician Alliance - St. Petersburg

Georgia

  • Pediatrics and Adolescent Medicine P.A. - Marietta

Texas

  • Arlington Family Research Center Inc. - Arlington

Virginia

  • Pediatric Research of Charlottesville - Charlottesville

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2014-05
Est. Completion 2017-05
Phase Phase 4
IBSA Institut Biochimique

8 total trials

What the finished NCT02132247 record still lists

NCT02132247 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 3 other Athletic Injuries trials with a reported enrollment target (45% lower).

The record links to 1 condition, with Athletic Injuries appearing as the primary indexed condition, and to 1 intervention - of which Diclofenac hydroxyethylpyrrolidine is the first listed.

NCT02132247 lists 10 locations in 6 states (Utah, Arkansas, Florida).

Frequently Asked Questions

What is clinical trial NCT02132247 about?

NCT02132247 is a clinical study titled "Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries". The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.

What is the current status of trial NCT02132247?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2014-05. Estimated completion is 2017-05.

What conditions does trial NCT02132247 study?

This clinical trial studies the following conditions: Athletic Injuries.

What interventions are being tested in trial NCT02132247?

The interventions under investigation include: Diclofenac hydroxyethylpyrrolidine (DRUG).

Who is sponsoring clinical trial NCT02132247?

This trial is sponsored by IBSA Institut Biochimique, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02132247 being conducted?

This trial has 10 study locations across Arkansas, Florida, Georgia, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Athletic Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02132247, the US trial registry maintained by the National Library of Medicine. NCT02132247 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.